MX2007001940A - 5-[3-(4-benciloxifeniltio)-fur-2-il]-imidazolidin-2,4-diona y analogos como inhibidores de macrofago elastasa. - Google Patents

5-[3-(4-benciloxifeniltio)-fur-2-il]-imidazolidin-2,4-diona y analogos como inhibidores de macrofago elastasa.

Info

Publication number
MX2007001940A
MX2007001940A MX2007001940A MX2007001940A MX2007001940A MX 2007001940 A MX2007001940 A MX 2007001940A MX 2007001940 A MX2007001940 A MX 2007001940A MX 2007001940 A MX2007001940 A MX 2007001940A MX 2007001940 A MX2007001940 A MX 2007001940A
Authority
MX
Mexico
Prior art keywords
benzyloxyphenylthio
imidazolidin
fur
dione
inhibitors
Prior art date
Application number
MX2007001940A
Other languages
English (en)
Inventor
Fude Yang
Original Assignee
Quest Pharmaceutical Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Pharmaceutical Services filed Critical Quest Pharmaceutical Services
Publication of MX2007001940A publication Critical patent/MX2007001940A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion describe 5-[3-(4-benciloxifeniltio)-fur-2- il]-imidazolidin-2,4-diona y analogos como inhibidores de macrofago elastasa.
MX2007001940A 2004-08-19 2005-08-17 5-[3-(4-benciloxifeniltio)-fur-2-il]-imidazolidin-2,4-diona y analogos como inhibidores de macrofago elastasa. MX2007001940A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60273604P 2004-08-19 2004-08-19
PCT/US2005/029259 WO2006023562A2 (en) 2004-08-19 2005-08-17 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase

Publications (1)

Publication Number Publication Date
MX2007001940A true MX2007001940A (es) 2007-07-24

Family

ID=35968136

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007001940A MX2007001940A (es) 2004-08-19 2005-08-17 5-[3-(4-benciloxifeniltio)-fur-2-il]-imidazolidin-2,4-diona y analogos como inhibidores de macrofago elastasa.

Country Status (17)

Country Link
US (1) US7179831B2 (es)
EP (1) EP1789036B1 (es)
JP (1) JP5042833B2 (es)
KR (1) KR101197325B1 (es)
CN (1) CN101014338B (es)
AT (1) ATE508744T1 (es)
AU (1) AU2005277432B2 (es)
BR (1) BRPI0514470B8 (es)
CA (1) CA2577430C (es)
DK (1) DK1789036T3 (es)
ES (1) ES2364068T3 (es)
HK (1) HK1107774A1 (es)
MX (1) MX2007001940A (es)
NZ (1) NZ553258A (es)
RU (1) RU2391339C2 (es)
SI (1) SI1789036T1 (es)
WO (1) WO2006023562A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090007281A1 (en) * 2006-01-13 2009-01-01 Battelle Memorial Institute Animal Model for Assessing Copd-Related Diseases
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
MX2019001957A (es) * 2016-08-19 2019-10-14 Foresee Pharmaceuticals Co Ltd Composicion farmaceutica y metodos de usos.
US10532102B2 (en) * 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
RU2735600C2 (ru) * 2016-09-23 2020-11-05 Какен Фармасьютикал Ко., Лтд. Способ получения (r)-5-(3,4-дифторфенил)-5-[(3-метил-2-оксопиридин-1(2h)-ил)метил]имидазолидин-2,4-диона и промежуточное соединение для его получения
TWI827601B (zh) 2018-05-15 2024-01-01 逸達生物科技股份有限公司 基質金屬蛋白酶(mmp)抑制劑及其使用方法
EP4058437A4 (en) 2019-11-14 2023-11-22 Foresee Pharmaceuticals Co., Ltd. MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF
EP4351566A1 (en) * 2021-06-08 2024-04-17 Foresee Pharmaceuticals Co., Ltd. Safe administration of mmp-12 inhibitor
RU2766551C1 (ru) * 2021-07-19 2022-03-15 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) 5-(4-хлорфенил)-3-((4-хлорфенил)амино)-5-(фенилтио)фуран-2(5н)-он, обладающий противомикробной активностью

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040577A1 (en) 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6352976B1 (en) * 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
US6897237B2 (en) 2000-04-28 2005-05-24 Shionogi & Co. Ltd. MMP-12 inhibitors
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
ATE445400T1 (de) 2001-05-25 2009-10-15 Bristol Myers Squibb Co Hydantion-derivate als hemmer von matrix- metalloproteinasen
EP1394159A1 (fr) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
AU2003282920A1 (en) 2002-10-04 2004-05-04 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)

Also Published As

Publication number Publication date
RU2007105822A (ru) 2008-09-27
AU2005277432B2 (en) 2011-11-24
AU2005277432A1 (en) 2006-03-02
EP1789036B1 (en) 2011-05-11
RU2391339C2 (ru) 2010-06-10
CA2577430C (en) 2010-12-07
WO2006023562A2 (en) 2006-03-02
BRPI0514470B8 (pt) 2021-07-20
CN101014338A (zh) 2007-08-08
CN101014338B (zh) 2010-06-16
US7179831B2 (en) 2007-02-20
EP1789036A2 (en) 2007-05-30
WO2006023562B1 (en) 2006-06-22
EP1789036A4 (en) 2008-08-27
US20060041000A1 (en) 2006-02-23
KR20070045330A (ko) 2007-05-02
HK1107774A1 (en) 2008-04-18
JP5042833B2 (ja) 2012-10-03
WO2006023562A3 (en) 2006-04-20
JP2008510701A (ja) 2008-04-10
BRPI0514470A (pt) 2008-06-10
SI1789036T1 (sl) 2011-09-30
ES2364068T3 (es) 2011-08-24
BRPI0514470B1 (pt) 2021-01-05
NZ553258A (en) 2011-02-25
CA2577430A1 (en) 2006-03-02
DK1789036T3 (da) 2011-06-27
KR101197325B1 (ko) 2012-11-05
ATE508744T1 (de) 2011-05-15

Similar Documents

Publication Publication Date Title
HK1107774A1 (en) 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues useful as inhibitors of macrophage elastase ;
TW200735865A (en) Compositions of an anticonvulsant and methods of using the same for reversing weight gain
ATE452631T1 (de) N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer
IL176571A0 (en) Substituted azole derivatives, compositions, and methods of use
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
WO2005087724A3 (en) Sulphonylpyrroles as hdac inhibitors
NO20081636L (no) FAP - inhibitorer
WO2006034093A3 (en) 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
TW200621253A (en) 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
EP1907369A4 (en) THIAZOLE DERIVATIVES USEFUL AS AMPK ACTIVATORS
DE602007011664D1 (de) Mykotoxin reduzierende zusammensetzung
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
WO2008005145A3 (en) Controlling memory parameters
ATE510822T1 (de) Kaliumkanalinhibitoren
UA98608C2 (en) Benzofused five-membered heterocycles and use thereof
WO2006029398A8 (en) All-trans-retinol : all-trans-13,14-dihydroretinol saturase and methods of its use
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
NO20061316L (no) Imidazopyndinderivater som induserbare NO-syntaseinhibitorer
AU2003234925A1 (en) TGF-Alpha EXPRESSION INHIBITORS
NL1027655A1 (nl) N-Alkylpyrrolen als HMG-CoA-reductaseremmers.
NO20071330L (no) Enzyminhibitor i leukemi
WO2007089743A3 (en) Potassium channel inhibitors
WO2006097293A3 (en) Combination of a steroid sulfatase inhibitor and an ascomycin
ATE493390T1 (de) 2,3-diaryl-pyrazolidine derivate als neurotensin abbauende enzyme-inhibitoren

Legal Events

Date Code Title Description
FG Grant or registration